8.6.1 ABSTRACT The Women's Cancer Program, led by Douglas Yee, M.D. and Levi Downs, M.D., has 32 members, representing 13 departments and four schools. As of September 30, 2007, these members have a total of $6.6 million in peer reviewed, funded research projects for the current budget period. Since June 2003, their research has resulted in 281 publications, of which 18% were intra-programmatic and 17% were interprogrammatic. This program was created by combining the members of the Breast Cancer program with new members interested in gynecologic malignancies. By creating the Women's Cancer program, we strengthened existing collaborations, enhanced the interaction between members performing similarly themed research, provided additional scientific mentorship for clinical investigators, and enhanced our capacity for translational research. The scientific goals of the program are to improve detection and prevention strategies, study mechanisms basic to cancer biology, translate research findings into innovative clinical strategies. To achieve these goals, the program is organized into four research themes: 1) functional imaging for cancer diagnosis, staging, and prediction of response to therapy, 2) angiogensis in breast and ovarian cancer, 3) gene expression, cell signaling, and steroid hormone receptor biology, and 4) translational research in cancer prevention and treatmet.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-13
Application #
8215017
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
13
Fiscal Year
2011
Total Cost
$42,451
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
How, Joan; Vij, Kiran R; Ebadi, Maryam et al. (2018) Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 93:E381-E383
Ustun, C; Brunstein, C; DeFor, T et al. (2018) Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant 53:97-100
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Kaizer, Alexander M; Hobbs, Brian P; Koopmeiners, Joseph S (2018) A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. Biometrics 74:1082-1094
Sperduto, Paul W; Deegan, Brian J; Li, Jing et al. (2018) Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro Oncol 20:1652-1660
Li, Danni; Huang, Fangying; Zhao, Yingchun et al. (2018) Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study. Clin Proteomics 15:31
Hwa Yun, Byeong; Guo, Jingshu; Bellamri, Medjda et al. (2018) DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans. Mass Spectrom Rev :
Yun, Byeong Hwa; Bellamri, Medjda; Rosenquist, Thomas A et al. (2018) Method for Biomonitoring DNA Adducts in Exfoliated Urinary Cells by Mass Spectrometry. Anal Chem 90:9943-9950
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplant 53:1069-1071
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933

Showing the most recent 10 out of 1013 publications